GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for 6.9 million on April 22, 2022. Pharming will receive one-off 6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.845 EUR | -1.63% | -4.20% | -18.04% |
May. 08 | Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.04% | 619M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- GIMV NV reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. for €6.9 million.